Citius Pharmaceuticals’ (CTXR) Hold Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their hold rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR) in a report issued on Friday,Benzinga reports.

Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Citius Pharmaceuticals in a research note on Tuesday, November 12th.

Citius Pharmaceuticals Stock Down 19.0 %

CTXR opened at $0.13 on Friday. Citius Pharmaceuticals has a 52-week low of $0.11 and a 52-week high of $1.07. The company has a 50 day moving average of $0.40 and a two-hundred day moving average of $0.58. The company has a market cap of $24.18 million, a P/E ratio of -0.56 and a beta of 1.66.

Citius Pharmaceuticals shares are set to reverse split on Tuesday, November 26th. The 1-25 reverse split was announced on Friday, November 22nd. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, November 25th.

Hedge Funds Weigh In On Citius Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Armistice Capital LLC acquired a new position in shares of Citius Pharmaceuticals in the second quarter worth about $5,928,000. Vanguard Group Inc. raised its holdings in Citius Pharmaceuticals by 1.5% in the first quarter. Vanguard Group Inc. now owns 7,005,119 shares of the company’s stock valued at $6,286,000 after acquiring an additional 104,889 shares in the last quarter. Geode Capital Management LLC grew its holdings in Citius Pharmaceuticals by 14.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,878,953 shares of the company’s stock worth $941,000 after acquiring an additional 232,656 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Citius Pharmaceuticals in the 2nd quarter worth about $118,000. Finally, Wealth Advisory Solutions LLC raised its stake in shares of Citius Pharmaceuticals by 33.1% in the 3rd quarter. Wealth Advisory Solutions LLC now owns 201,000 shares of the company’s stock valued at $101,000 after purchasing an additional 50,000 shares in the last quarter. 16.88% of the stock is owned by hedge funds and other institutional investors.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.